121 completed, 83 unknown, 27 terminated, 15 withdrawn. 265 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 265 | Completed 121, Unknown 83, Terminated 27, Withdrawn 15, Recruiting 9, Active not recruiting 6, Suspended 3, Not yet recruiting 1 |
Follow Coronavirus Infections: new trials by email Literature Review of Coronavirus Infections trials Research Report on Coronavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations mRNA-1273, mRNA-1283 - SARS-CoV-2 | Phase 4 | Recruiting | ModernaTX, Inc. | 600 | 2026-10-09 | 2026-11-04 |
| Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M - COVID-19 | Phase 4 | Active not recruiting | Sanofi | 669 | 2026-10-01 | 2026-11-12 |
| Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) - COVID-19, Influenza | Phase 4 | Not yet recruiting | Tor Biering-Sørensen | 410000 | 2026-09-01 | 2026-08-27 |
| A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age BNT162b2 Vaccine, Tdap Vaccine - COVID-19 Vaccines | Phase 4 | Recruiting | BioNTech SE | 200 | 2026-07-23 | 2026-08-07 |
| Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial Corticosteroid - Hypoxemia, Severe Acute Respiratory Syndrome | Phase 4 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-01 | 2026-11-17 | |
| Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 mRNA-1273 (Moderna COVID-19 vaccine) - COVID-19 | Phase 4 | Completed | Tor Biering-Sørensen | 41060 | 2025-12-11 | 2026-10-06 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) mRNA-1273, mRNA-1283, Placebo - SARS-CoV-2 | Phase 4 | Active not recruiting | ModernaTX, Inc. | 30000 | 2025-11-26 | 2026-09-28 |
| Efficacy and Safety of NVX-CoV2705 NVX-CoV2705, Placebo - COVID-19, Sars-CoV-2 Infection | Phase 4 | Terminated | Novavax | 6500 | 2025-11-20 | 2026-10-23 |
| Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine - COVID -19, COVID - 19 | Phase 4 | Recruiting | Henry M. Jackson Foundation for the Advancement of Military Medicine | 54 | 2025-11-12 | 2026-11-02 |
| Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens Ruconest - Post SARS-CoV2 (COVID-19), Post-Viral Fatigue Syndrome | Phase 4 | Recruiting | IMMUNOe Research Centers | 30 | 2025-11-05 | 2026-11-12 |
| COVID-19 Reactogenicity Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283 - COVID-19 | Phase 4 | Active not recruiting | Marcel Curlin | 1000 | 2025-10-01 | 2026-03-04 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations mRNA-1283.251 Variant-containing Formulation - COVID-19 | Phase 4 | Completed | ModernaTX, Inc. | 832 | 2025-07-21 | 2026-07-07 |
| Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial Nirmatrelvir/ritonavir, Remdesivir - SARS CoV-2 Post-Acute Sequelae | Phase 4 | Recruiting | Mount Sinai Hospital, Canada | 118 | 2025-01-03 | 2025-01-24 |
| An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. Remdesivir - SARS-CoV-2 Infection, COVID-19 | Phase 4 | Completed | University of Derby | 73 | 2024-10-08 | 2026-02-20 |
| Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP - Ebola Virus Disease, COVID-19 | Phase 4 | Unknown | University of Birmingham | 72 | 2024-10-01 | 2024-09-19 |
| Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine - COVID-19, Vaccine-Preventable Diseases | Phase 4 | Completed | Novavax | 660 | 2024-09-19 | 2026-06-02 |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations mRNA-1273 Variant-containing Formulation - SARS-CoV-2 | Phase 4 | Recruiting | ModernaTX, Inc. | 1144 | 2024-09-09 | 2026-03-27 |
| Anti-viral Action Against Type 1 Diabetes Autoimmunity Comirnaty Injectable Product, Sodium Chloride 0.9% Inj - Diabetes Mellitus, Type 1 | Phase 4 | Recruiting | Technical University of Munich | 2252 | 2024-05-08 | 2025-09-23 |
| Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program. Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine - COVID-19, Long Haul | Phase 4 | Recruiting | Well- Konnect Healthcare Services and Research Firm | 100 | 2024-03-01 | 2024-11-27 |
| Tetrandrine Tablets Used in Hospitalized Adults With COVID-19 Tetrandrine - COVID-19 | Phase 4 | Withdrawn | Peking University Third Hospital | 2023-12-31 | 2024-10-01 |
Showing 20 of 265. Sign in to see all of them.
COVID-19 (243) · Severe Acute Respiratory Syndrome (10) · Post-Acute COVID-19 Syndrome (9) · Influenza, Human (8) · Virus Diseases (8) · Pneumonia (7) · Respiratory Tract Infections (6) · Infections (5) · Pneumonia, Viral (5) · Respiratory Distress Syndrome (5) · Anosmia (4) · HIV Infections (4) · Pulmonary Disease, Chronic Obstructive (4) · Bronchitis, Chronic (3)
Coronaviridae Infections (263) · Nidovirales Infections (263) · RNA Virus Infections (263) · Infections (260) · Virus Diseases (257) · Respiratory Tract Diseases (251) · Lung Diseases (248) · Respiratory Tract Infections (247) · Pneumonia, Viral (243) · Pneumonia (241) · Pathological Conditions, Signs and Symptoms (43) · Pathologic Processes (33) · Disease Attributes (23) · Chronic Disease (18)
sinovac COVID-19 vaccine (20) · Hydroxychloroquine (19) · 2019-nCoV Vaccine mRNA-1273 (15) · BNT162 Vaccine (15) · Standard of Care (11) · Dexamethasone (10) · Enoxaparin (8) · Sodium Chloride (8) · Ivermectin (7) · Heparin (6) · Lopinavir (6) · Vaccines (6) · remdesivir (6) · Methylprednisolone (5) · Vitamin D (5)
China National Biotec Group Company Limited (10) · Sinovac Research and Development Co., Ltd. (9) · Jiangsu Province Centers for Disease Control and Prevention (8) · ClinAmygate (5) · ModernaTX, Inc. (4) · Shahid Beheshti University of Medical Sciences (4) · Sinovac Life Sciences Co., Ltd. (4) · Ain Shams University (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Novartis Pharmaceuticals (3) · Sinovac Biotech Co., Ltd (3) · BioNTech SE (2) · Brazilian Clinical Research Institute (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Clinical Urology and Epidemiology Working Group (2)
United States (65) · China (51) · Egypt (16) · Spain (16) · Brazil (15) · Canada (8) · Argentina (6) · Belgium (6) · Denmark (6) · Netherlands (6) · Pakistan (6) · United Kingdom (6) · Germany (5) · India (5) · Russia (5)
Jing-Xin Li, PhD (5) · Hanqing He (4) · Seyed Sina Naghibi Irvani, MD, MPH, MBA (4) · Ruizhi Zhang (3) · Aijaz Zeeshan Khan Chachar, MBBS,FCPS (2) · Avni Thakore, MD (2) · Dongjuan Zhang (2) · Emad R Issak, MD (2) · Fubing Wang (2) · George Sakoulas, MD (2) · Hongxing Pan, Master (2) · Ilad Alavi Darazam, MD (2) · Jens Lundgren, Professor (2) · Jiang Wu, Master (2)
PMID 35244208, PMID 34473343, PMID 33502773, PMID 37591523, PMID 36658045, PMID 37489818, PMID 11225528, PMID 11505791, PMID 16444180, PMID 16490989, PMID 17099299, PMID 20354090, PMID 23017003, PMID 23433693, PMID 27449641, PMID 28473851, PMID 29633177, PMID 30639191, PMID 31761015, PMID 32043986, PMID 32047895, PMID 32159775, PMID 32171076, PMID 32178593, PMID 32213556, PMID 32224164, PMID 32312790, PMID 32326426, PMID 32356926, PMID 32407672, PMID 32422305, PMID 32425001, PMID 32503662, PMID 32503663, PMID 32505069, PMID 32512291, PMID 32513231, PMID 32517353, PMID 32559419, PMID 32641154, PMID 32738928, PMID 32758441, PMID 32799933, PMID 32838353, PMID 32859459, PMID 32895056, PMID 33072620, PMID 33082342, PMID 33215159, PMID 33388170
1OT2HL156812-01 (1), 2025 (1), R01MD016872 (1)